Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Total Current Liabilities (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Total Current Liabilities for 6 consecutive years, with $10.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Current Liabilities fell 28.36% year-over-year to $10.8 million, compared with a TTM value of $10.8 million through Sep 2025, down 28.36%, and an annual FY2024 reading of $15.7 million, up 24.28% over the prior year.
  • Total Current Liabilities was $10.8 million for Q3 2025 at Barinthus Biotherapeutics, down from $12.7 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $18.6 million in Q3 2023 and bottomed at $6.4 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $12.6 million, with a median of $12.2 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities soared 120.2% in 2022, then fell 28.36% in 2025.
  • Year by year, Total Current Liabilities stood at $11.2 million in 2021, then rose by 9.72% to $12.2 million in 2022, then rose by 2.91% to $12.6 million in 2023, then increased by 24.28% to $15.7 million in 2024, then plummeted by 31.03% to $10.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for BRNS at $10.8 million in Q3 2025, $12.7 million in Q2 2025, and $12.0 million in Q1 2025.